000916866 001__ 916866
000916866 005__ 20230224084253.0
000916866 0247_ $$2doi$$a10.1007/s11307-022-01749-7
000916866 0247_ $$2ISSN$$a1536-1632
000916866 0247_ $$2ISSN$$a1860-2002
000916866 0247_ $$2Handle$$a2128/33592
000916866 0247_ $$2pmid$$a35771317
000916866 0247_ $$2WOS$$aWOS:000819277600001
000916866 037__ $$aFZJ-2023-00158
000916866 082__ $$a570
000916866 1001_ $$0P:(DE-HGF)0$$aWegen, Simone$$b0$$eCorresponding author
000916866 245__ $$aHead-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer
000916866 260__ $$aCham$$bSpringer Nature Switzerland$$c2022
000916866 3367_ $$2DRIVER$$aarticle
000916866 3367_ $$2DataCite$$aOutput Types/Journal article
000916866 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1673619836_26271
000916866 3367_ $$2BibTeX$$aARTICLE
000916866 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000916866 3367_ $$00$$2EndNote$$aJournal Article
000916866 520__ $$aIntroduction: In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomography (PET/CT) imaging using [68 Ga]-radiolabeled inhibitors of FAP ([68 Ga]Ga-FAPI-46) in HNCs. This study aims to compare [68 Ga]Ga-FAPI-46 PET/CT and [18F]-fluorodeoxy-D-glucose ([18F]F-FDG) PET/CT with a focus on improved target volume definition and radiotherapy planning in patients with HNC referred for chemoradiation.Methods: A total of 15 patients with HNCs received both [68 Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT with a thermoplastic mask, in addition to initial tumor staging by conventional imaging with contrast-enhanced CT and/or MRI. Mean intervals between FAPI/FDG and FAPI/conventional imaging were 4 ± 20 and 17 ± 18 days, respectively. Location and number of suspicious lesions revealed by the different procedures were recorded. Subsequently, expert-generated gross tumor volumes (GTVs) based on conventional imaging were compared to those based on [18F]F-FDG and [68 Ga]Ga-FAPI-46 PET/CT to measure the impact on subsequent radiation planning.Results: All patients had focal FAPI uptake above background in tumor lesions. Compared to FDG, tumor uptake (median SUVmax 10.2 vs. 7.3, p = 0.008) and tumor-to-background ratios were significantly higher with FAPI than with FDG (SUVmean liver: 9.3 vs. 3.2, p < 0.001; SUVmean bloodpool: 6.9 vs. 4.0, p < 0.001). A total of 49 lesions were recorded. Of these, 40 (82%) were FDG+ and 41 (84%) were FAP+. There were 5 (10%) FAP+/FDG- lesions and 4 (8%) FAP-/FDG+ lesions. Volumetrically, a significant difference was found between the GTVs (median 57.9 ml in the FAPI-GTV, 42.5 ml in the FDG-GTV, compared to 39.2 ml in the conventional-GTV). Disease stage identified by FAPI PET/CT was mostly concordant with FDG PET/CT. Compared to conventional imaging, five patients (33%) were upstaged following imaging with FAPI and FDG PET/CT.Conclusion: We demonstrate that [68 Ga]Ga-FAPI-46 -PET/CT is useful for detecting tumor lesions in patients with HNCs. There is now a need for prospective randomized studies to confirm the role of [68 Ga]Ga-FAPI-46 PET/CT in relation to [18F]F-FDG PET/CT in HNCs and to evaluate its impact on clinical outcome.Keywords: FAPI; FDG/PET; Head and neck cancer; PET-based; Radiotherapy planning.
000916866 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000916866 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000916866 7001_ $$0P:(DE-HGF)0$$avan Heek, Lutz$$b1
000916866 7001_ $$0P:(DE-HGF)0$$aLinde, Philipp$$b2
000916866 7001_ $$0P:(DE-HGF)0$$aClaus, Karina$$b3
000916866 7001_ $$0P:(DE-HGF)0$$aAkuamoa-Boateng, Dennis$$b4
000916866 7001_ $$0P:(DE-HGF)0$$aBaues, Christian$$b5
000916866 7001_ $$0P:(DE-HGF)0$$aSharma, Shachi Jenny$$b6
000916866 7001_ $$0P:(DE-HGF)0$$aSchomäcker, Klaus$$b7
000916866 7001_ $$0P:(DE-HGF)0$$aFischer, Thomas$$b8
000916866 7001_ $$0P:(DE-HGF)0$$aRoth, Katrin Sabine$$b9
000916866 7001_ $$0P:(DE-HGF)0$$aKlußmann, Jens Peter$$b10
000916866 7001_ $$0P:(DE-HGF)0$$aMarnitz, Simone$$b11
000916866 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b12
000916866 7001_ $$0P:(DE-HGF)0$$aKobe, Carsten$$b13
000916866 773__ $$0PERI:(DE-600)2079211-6$$a10.1007/s11307-022-01749-7$$gVol. 24, no. 6, p. 986 - 994$$n6$$p986 - 994$$tMolecular imaging & biology$$v24$$x1536-1632$$y2022
000916866 8564_ $$uhttps://juser.fz-juelich.de/record/916866/files/s11307-022-01749-7.pdf$$yOpenAccess
000916866 909CO $$ooai:juser.fz-juelich.de:916866$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000916866 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b12$$kFZJ
000916866 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000916866 9141_ $$y2022
000916866 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000916866 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000916866 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL IMAGING BIOL : 2021$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-11$$wger
000916866 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000916866 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000916866 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000916866 920__ $$lyes
000916866 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000916866 980__ $$ajournal
000916866 980__ $$aVDB
000916866 980__ $$aUNRESTRICTED
000916866 980__ $$aI:(DE-Juel1)INM-2-20090406
000916866 9801_ $$aFullTexts